MARKET NEWS

Cognate BioServices & Its Gene Therapy Division Cobra Biologics Announce Major Expansion
Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License & Collaboration Agreement
Neuropathix Announces Publication of Its Global PCT Patent for a Novel Hops-Inspired Neuroprotectant
Quantum Genomics Launches Phase 3 Pivotal REFRESH Study
Gritstone Advances Second-Generation COVID-19 Vaccine
Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial 

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization, with sites in Belgium, United States, Japan, and India, providing comprehensive process development services, cGMP manufacturing, and drug product fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including Corynex protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADCs), high potency APIs (HPAPIs), continuous flow manufacturing, and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory

Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory

Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to….

ViGeneron Announces Research Collaboration With Daiichi Sankyo to Evaluate Novel Ophthalmic Gene Therapy

ViGeneron Announces Research Collaboration With Daiichi Sankyo to Evaluate Novel Ophthalmic Gene Therapy

ViGeneron GmbH recently announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited for delivering….

Molecular Templates Announces FDA Acceptance of IND Application for a PD-L1-Targeted Engineered Toxin Body Enabled With Proprietary Antigen Seeding Technology

Molecular Templates Announces FDA Acceptance of IND Application for a PD-L1-Targeted Engineered Toxin Body Enabled With Proprietary Antigen Seeding Technology

Molecular Templates, Inc. recently announced the US FDA has accepted its Investigational New Drug (IND) application for MT-6402, a next-generation ETB targeting PD-L1 that is enabled with….

Clene Nanomedicine Receives Patent Notice of Allowance for using Gold Nanocrystals for Treating MS

Clene Nanomedicine Receives Patent Notice of Allowance for using Gold Nanocrystals for Treating MS

Clene Inc. recently announced its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, was issued a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its invention for….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 3 – Analytical Testing
February 10 – Injection Devices